RO 7812653
Alternative Names: RO-7812653Latest Information Update: 30 Jan 2026
At a glance
- Originator Roche
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 19 Nov 2025 Preclinical trials in Alzheimer's disease in Switzerland (unspecified route) prior to November 2025
- 19 Nov 2025 Roche plans a phase I trial for Alzheimer's disease (Intrathecal) in January 2026 (NCT07234942)